.
MergerLinks Header Logo

Announced

Cerba Healthcare to acquire Viroclinics-DDL from Summit Partners.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private Equity

Single Bidder

Pending

Biotechnology

Cross Border

Acquisition

contract research organization

Majority

Friendly

Private

Netherlands

testing inspection and certification

Test Inspection and Certification (TIC)

Synopsis

Edit

Cerba Healthcare, a medical diagnosis provider, agreed to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization, from Summit Partners, a private equity firm. Financial terms were not disclosed. "With Cerba Research, we have a new foundation for further global expansion to North America, Asia, and Africa with unrivalled expertise, capacity and capabilities. Together, we will be able to offer integrated solutions to the life science industry, accelerating antiviral, vaccine, and other R&D programs, while offering unmatched logistics solutions securing the integrity of fragile samples. Our 390+ scientists and experts look forward to joining Cerba Research in our continuous quest to provide the best possible science and service to our customers," Davide Molho, Viroclinics-DDL CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US